STEFANIE HOLLENBACH, M.D.

M.D.

Obstetrics & Gynecology Physician

NPI: 1306289376IndividualAccepts Medicare

Specialties, Licenses & Credentials

Medical Physician Assistant

Physician Assistant — Medical

Code: 363AM0700X

290009(NY)

Student in an Organized Health Care Education/Training Program

Code: 390200000X

Obstetrics & Gynecology PhysicianPrimary

Obstetrics & Gynecology

Code: 207V00000X

290009(NY)

Education

OTHER

Class of 2013

Research & Publications (20)

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

PMID 19297154·Bioorg Med Chem Lett·2009

4-observational

Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.

PMID 15056002·J Med Chem·2004

7-preclinical

N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.

PMID 15080981·Bioorg Med Chem Lett·2004

8-other

Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.

PMID 15341941·Bioorg Med Chem Lett·2004

7-preclinical

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.

PMID 15013007·Bioorg Med Chem Lett·2004

7-preclinical

Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.

PMID 14736451·J Am Coll Cardiol·2004

7-preclinical

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.

PMID 15013006·Bioorg Med Chem Lett·2004

7-preclinical

Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.

PMID 12750119·Arterioscler Thromb Vasc Biol·2003

4-observational

Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.

PMID 12565972·Bioorg Med Chem Lett·2003

7-preclinical

Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker.

PMID 12619891·Mol Cell Biochem·2003

8-other

Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.

PMID 12639567·Bioorg Med Chem Lett·2003

7-preclinical

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

PMID 12166950·J Med Chem·2002

7-preclinical

Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.

PMID 12039584·Bioorg Med Chem Lett·2002

7-preclinical

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

PMID 12124172·Cancer Cell·2002

7-preclinical

Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors.

PMID 12031331·Bioorg Med Chem Lett·2002

4-observational

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

PMID 12097282·Cancer Res·2002

7-preclinical

Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.

PMID 12368212·Am J Pathol·2002

7-preclinical

Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.

PMID 11527714·Bioorg Med Chem Lett·2001

7-preclinical

PMID 11532868·Carcinogenesis·2001

7-preclinical

Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.

PMID 11504817·J Pharmacol Exp Ther·2001

7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address: 601 ELMWOOD AVE
ROCHESTER, NY 14642
Phone: (585) 487-3350

Location

Practice Location

601 ELMWOOD AVE, ROCHESTER, NY

(585) 487-3350

Quick Facts

NPI: 1306289376
Entity Type: Individual
Gender: Female
Medicare: Accepted
Specialties: 3
Locations: 1
Years in Practice: 13
Publications: 20

Are you this provider?

Claim Your Profile